Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib versus bosutinib in previously treated chronic-phase chronic myeloid leukemia
NL-OMON52915Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of asciminib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Major molecular response rate at week 24. Started May 2018; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON52915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52915.